So tell me about SLE disease

Reading File

Finding Sources

Searching PubMed

"systemic lupus erythematosus"[MeSH Terms]

Finding Sources

Searching PubMed

"lupus erythematosus, systemic"[MeSH Terms] AND treatment

Finding Sources

Reading File

Loading Image

Reading File

Loading Image

Reading File

I now have comprehensive content from multiple textbooks. Let me compile the full, authoritative answer on SLE.

Systemic Lupus Erythematosus (SLE)

SLE is a chronic, remitting and relapsing, multisystem autoimmune disease. It is considered the classic human immune complex disease - autoantibodies form immune complexes that deposit throughout the body, causing widespread tissue injury. It predominantly affects women of childbearing age (female:male ratio ~10:1), with an incidence of ~1 in 700 women aged 20-60 in the US, and is significantly more common and severe in Black women (~1 in 250).

Pathogenesis

SLE results from a complex interplay of genetic susceptibility, environmental triggers, and failure of immune self-tolerance.

Genetic Factors

HLA associations: HLA-DR2 and HLA-DR3 confer an odds ratio of 2-3; both together raise it to ~5
Complement deficiencies: Inherited deficiencies of C1q, C2, or C4 occur in ~5% of patients and lead to defective clearance of immune complexes and apoptotic cells, and failure of B cell tolerance
FcγRIIB polymorphism: Impairs control of B cell activation and failure to attenuate inflammatory responses
PTPN22 and many other genes identified in genome-wide association studies
Deficiencies in DNases (e.g., TREX1) reduce clearance of nuclear material

Environmental Triggers

UV light induces apoptotic death of skin cells and release of nuclear antigens, explaining photosensitivity and flares

Key Immunological Mechanisms

IFN-α / Type I Interferon Signature: A hallmark of SLE is a striking "interferon gene signature" in blood cells, indicating exposure to IFN-α produced by plasmacytoid dendritic cells. Plasmacytoid DCs from SLE patients produce abnormally large amounts of IFN-α.

TLR Activation: Toll-like receptors that recognize self-nucleic acids (TLR9 for DNA, TLR7 for RNA) activate self-reactive B cells. When nuclear material from apoptotic cells is inadequately cleared, it activates these TLRs on autoreactive B and T lymphocytes.

Neutrophil Extracellular Traps (NETs): A major recent insight is the role of neutrophils - especially Low-Density Granulocytes (LDGs). These cells form NETs that carry modified self-antigens, activate plasmacytoid DCs via LL-37-DNA complexes to produce more Type I IFN, and cause direct tissue damage and vasculopathy.

The diagram below illustrates how NETs drive the pathogenesis of SLE and related autoimmune diseases:

Neutrophils/LDGs and NETs in SLE pathogenesis - showing how microbes, immune complexes, and cell damage products activate neutrophils to form NETs, which then drive Type I IFN production via dendritic cells, autoantibodies via B cells, and vasculopathy

The net result is a cycle: defective clearance of nuclear material → activation of self-reactive B and T cells → production of anti-nuclear autoantibodies → immune complex deposition → complement activation → tissue damage across multiple organs.

Clinical Manifestations

SLE can affect virtually every organ system. The disease course is one of flares and remissions.

Mucocutaneous (80% of patients - highest diagnostic value)

Malar (butterfly) rash: Erythema over cheeks and bridge of nose, characteristically sparing the nasolabial folds (unlike dermatomyositis). Represents acute cutaneous LE.
Discoid rash: Scarring, disk-shaped plaques; can occur without systemic disease
Photosensitivity: UV exposure triggers skin eruptions and systemic flares
Oral ulcers: 20-30% of patients; usually painless
Bullous lupus: Subepidermal vesicles/bullae, often on sun-exposed areas, with neutrophils at the dermal-epidermal junction - responds dramatically to dapsone
Non-scarring alopecia and "lupus hairs" (frontal short broken hairs)
Vascular lesions: Periungual telangiectasias, livedo reticularis (50% of patients)

Clinical photo - Bullous lupus erythematosus:

Bullous lupus erythematosus - tense bullae and vesicles on the arm

Musculoskeletal

Arthritis/arthralgia: One of the most common features; typically non-erosive, symmetric, involving small joints of the hands, wrists, and knees
Jaccoud arthropathy (non-erosive deformities) can occur

Renal (Lupus Nephritis)

This is the most serious manifestation and a major driver of morbidity and mortality.

WHO/ISN Classification by biopsy:

Class	Description
I	Minimal mesangial
II	Mesangial proliferative (immune complex deposition with mesangial hypercellularity)
III	Focal glomerulonephritis (<50% of glomeruli)
IV	Diffuse glomerulonephritis (≥50% of glomeruli) - most severe
V	Membranous lupus nephritis
VI	Advanced sclerotic

Renal evaluation includes urinalysis with microscopy (look for red cell casts indicating proliferative GN), spot urine protein:creatinine ratio, and serum creatinine. Renal biopsy guides management and prognosis.

Hematologic

Autoimmune hemolytic anemia: Direct Coombs positive, caused by anti-erythrocyte antibodies
Thrombocytopenia: Anti-platelet antibodies; can be severe
Leukopenia/lymphopenia: Common
Antiphospholipid syndrome (APS): Occurs in ~21% - causes arterial/venous thrombosis and recurrent pregnancy loss

Neuropsychiatric Lupus (NPSLE)

Seizures, psychosis, cognitive dysfunction, delirium, depression, transverse myelitis, stroke
MRI shows white matter lesions, cerebral infarction, venous sinus thrombosis in 19-70% of patients
Pathogenesis involves immune complex deposition, antiphospholipid antibody-related thrombosis, and direct neuronal injury

Cardiopulmonary

Pleuritis/pleural effusion (sterile, exudative)
Pericarditis/pericardial effusion
Libman-Sacks endocarditis: Non-infective verrucous lesions on cardiac valves
Accelerated atherosclerosis and coronary artery disease (related to chronic inflammation + LDG-driven vasculopathy)
Interstitial lung disease, pulmonary hypertension

Constitutional

Fever, fatigue, weight loss - common during flares

Autoantibodies in SLE

Autoantibody	Frequency	Notes
ANA (antinuclear antibodies)	~99%	Entry criterion for classification; sensitive but not specific
Anti-dsDNA	~70%	High specificity for SLE; titers correlate with disease activity, especially nephritis
Anti-Sm (Smith)	~38%	Highly specific for SLE
Anti-Ro (SSA)	~49%	Associated with neonatal lupus, photosensitivity
Anti-La (SSB)	~35%	Associated with Sjogren overlap
Anti-RNP (U1-RNP)	~33%	High titers associated with MCTD
Antiphospholipid (aCL, anti-β2GPI, lupus anticoagulant)	~21%	Thrombosis risk, pregnancy loss
Anti-ribosomal P	~10%	Associated with neuropsychiatric lupus

Classification / Diagnostic Criteria

The 2019 EULAR/ACR Classification Criteria are the current standard. ANA titer ≥1:80 is the entry criterion. Points are assigned across clinical and immunological domains, and a score ≥10 classifies SLE.

Diagnostic algorithm (EULAR/ACR 2019):

Diagnostic algorithm for SLE - EULAR/ACR 2019 criteria flowchart showing ANA testing, scoring, and classification thresholds

Key scoring points (within each domain, count only the highest):

Feature	Points
Clinical
Acute cutaneous lupus	6
Joint involvement	6
Renal biopsy class III/IV nephritis	10
Renal biopsy class II/V nephritis	8
Proteinuria >0.5 g/24h	4
Pleural/pericardial effusion	5
Acute pericarditis	6
Seizure	5
Psychosis	3
Autoimmune hemolysis	4
Thrombocytopenia	4
Leukopenia	3
Immunological
Anti-dsDNA antibody	6
Low C3 AND low C4	4
Low C3 OR low C4	3
Anticardiolipin/anti-β2GPI antibodies	2

Classify as SLE if score ≥10 (with at least one clinical criterion).

Treatment

Management is tailored to disease severity and organ involvement.

Non-pharmacological

Avoid UV light exposure; use sunscreen consistently
Rest during flares; maintain cardiovascular health
Patient education about disease triggers and monitoring

Conventional Medical Therapy

1. NSAIDs - for mild symptoms, arthralgia, fever, serositis (use cautiously given renal disease risk)

2. Hydroxychloroquine (HCQ) - the cornerstone of SLE therapy

Dose: 200-400 mg/day (≤5 mg/kg actual body weight)
Reduces flares, damage accrual, and mortality
Safe in pregnancy; annual ophthalmology screening needed

3. Corticosteroids

Oral prednisone 5-30 mg/day for constitutional symptoms, arthritis, serositis, skin disease
High-dose IV methylprednisolone ("pulse") for severe flares and organ-threatening disease
Side effects: osteonecrosis, osteoporosis, cataracts, diabetes, hypertension - limit long-term use

4. Immunosuppressives

Mycophenolate mofetil (MMF): First-line for lupus nephritis (induction + maintenance)
Cyclophosphamide: IV pulses for severe proliferative nephritis or severe NPSLE
Azathioprine: Maintenance therapy, safe in pregnancy
Methotrexate (15-25 mg/week): Cutaneous and articular disease; not for pregnancy
Calcineurin inhibitors (tacrolimus, cyclosporine, voclosporin): Lupus nephritis, particularly membranous

Biologic Therapies

Agent	Mechanism	Indication
Belimumab	Anti-BAFF (blocks B-cell survival)	Moderately active SLE; approved for lupus nephritis
Anifrolumab	Anti-type I IFN receptor	Moderate-to-severe SLE on standard background therapy
Rituximab	Anti-CD20 (B cell depletion)	Refractory nephritis/cytopenias (off-label)
Obinutuzumab	Anti-CD20 (enhanced B cell depletion)	Lupus nephritis (Phase III RCT, PMID 39927615, NEJM 2025 - showed efficacy and safety)

A 2025 Phase III RCT published in the New England Journal of Medicine found obinutuzumab effective and safe in active lupus nephritis, representing a significant advance in B cell-targeted therapy for this indication.

Adjunctive and Special Situations

Hypertension control: ACE inhibitors or ARBs (also reduce proteinuria)
Thrombosis prevention: Long-term anticoagulation (warfarin) for patients with APS and prior thrombosis
IVIG: For refractory disease or lupus-related TTP
Plasmapheresis: Life-threatening complications with clearly attributable pathogenic antibodies

Pregnancy in SLE

Increased risk of pre-eclampsia, fetal loss, preterm birth - especially with active disease or APS
Pregnancy should be planned during disease remission
Low-activity disease without antiphospholipid antibodies: combined oral contraceptives do not significantly increase flare risk
Moderate/severe disease: progestin-only contraception recommended
Neonatal lupus (anti-Ro/SSA mediated): neonatal heart block and transient skin rash

Prognosis & Monitoring

10-year survival is now >90% in developed countries with modern therapy (vs. ~50% in the 1950s)
Major causes of death: infection (from immunosuppression), renal failure, cardiovascular disease (accelerated atherosclerosis), and disease flares
Disease activity monitoring: SLEDAI score, anti-dsDNA titers, complement levels (C3/C4 drop during active disease), urinalysis, CBC, renal function
Damage accrual (irreversible organ damage) measured by SLICC Damage Index

Sources:

Cellular and Molecular Immunology, 10e (Abbas & Lichtman), p. 1274-1275 - Pathogenesis
Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set - Neutrophil/NET pathogenesis
GOLDMAN-CECIL MEDICINE, 2-Volume Set - Classification criteria, treatment
Andrews' Diseases of the Skin - Cutaneous manifestations
Obinutuzumab RCT: Furie RA et al., N Engl J Med, 2025 [PMID 39927615]
Su X et al., Mol Biomed 2024 - Pathogenesis and targeted therapy review [PMID 39472388]

Create a mind map for this

Running Command

ls /home/daytona/workspace/ 2>/dev/null || echo "workspace empty or not found"

Writing File

~/sle-mindmap/index.html

<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>SLE Mind Map</title>
<style>
  * { margin: 0; padding: 0; box-sizing: border-box; }
  body {
    background: #0f1117;
    font-family: 'Segoe UI', system-ui, sans-serif;
    overflow: hidden;
    width: 100vw;
    height: 100vh;
  }
  #canvas-wrapper {
    width: 100%;
    height: 100%;
    position: relative;
    overflow: hidden;
    cursor: grab;
  }
  #canvas-wrapper:active { cursor: grabbing; }
  svg#mindmap {
    position: absolute;
    top: 0; left: 0;
    width: 100%; height: 100%;
  }
  .controls {
    position: fixed;
    bottom: 24px;
    left: 50%;
    transform: translateX(-50%);
    display: flex;
    gap: 10px;
    z-index: 100;
  }
  .controls button {
    background: #1e2130;
    border: 1px solid #3a3f55;
    color: #cdd6f4;
    padding: 8px 18px;
    border-radius: 20px;
    cursor: pointer;
    font-size: 14px;
    transition: background 0.2s;
  }
  .controls button:hover { background: #2a2f45; }
  .legend {
    position: fixed;
    top: 20px;
    right: 20px;
    background: #1e2130cc;
    border: 1px solid #3a3f55;
    border-radius: 12px;
    padding: 14px 18px;
    color: #cdd6f4;
    font-size: 12px;
    z-index: 100;
  }
  .legend h4 { margin-bottom: 8px; color: #89b4fa; font-size: 13px; }
  .legend-item { display: flex; align-items: center; gap: 8px; margin: 4px 0; }
  .legend-dot { width: 12px; height: 12px; border-radius: 50%; flex-shrink: 0; }
  .title-badge {
    position: fixed;
    top: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: linear-gradient(135deg, #7c3aed, #a855f7);
    color: white;
    padding: 8px 24px;
    border-radius: 24px;
    font-size: 15px;
    font-weight: 700;
    letter-spacing: 1px;
    z-index: 100;
    box-shadow: 0 4px 20px #7c3aed66;
  }
  .tooltip {
    position: fixed;
    background: #1e2130ee;
    border: 1px solid #4a4f6a;
    border-radius: 10px;
    padding: 10px 14px;
    color: #cdd6f4;
    font-size: 12.5px;
    max-width: 260px;
    line-height: 1.5;
    pointer-events: none;
    z-index: 200;
    display: none;
    box-shadow: 0 8px 24px #00000088;
  }
  .tooltip b { color: #89b4fa; display: block; margin-bottom: 4px; font-size: 13px; }
</style>
</head>
<body>

<div class="title-badge">🔬 Systemic Lupus Erythematosus (SLE)</div>

<div class="legend">
  <h4>Branches</h4>
  <div class="legend-item"><div class="legend-dot" style="background:#f38ba8"></div> Pathogenesis</div>
  <div class="legend-item"><div class="legend-dot" style="background:#fab387"></div> Clinical Features</div>
  <div class="legend-item"><div class="legend-dot" style="background:#a6e3a1"></div> Autoantibodies</div>
  <div class="legend-item"><div class="legend-dot" style="background:#89dceb"></div> Diagnosis</div>
  <div class="legend-item"><div class="legend-dot" style="background:#cba6f7"></div> Treatment</div>
  <div class="legend-item"><div class="legend-dot" style="background:#f9e2af"></div> Prognosis</div>
</div>

<div id="canvas-wrapper">
  <svg id="mindmap"></svg>
</div>

<div class="controls">
  <button onclick="zoomIn()">+ Zoom In</button>
  <button onclick="resetView()">⟳ Reset</button>
  <button onclick="zoomOut()">− Zoom Out</button>
</div>

<div class="tooltip" id="tooltip"></div>

<script>
const W = window.innerWidth;
const H = window.innerHeight;
const cx = W / 2;
const cy = H / 2;

// ── Data ──────────────────────────────────────────────────────────────────────
const mindmapData = {
  id: "root",
  label: "SLE",
  sublabel: "Systemic Lupus\nErythematosus",
  color: "#cba6f7",
  glow: "#7c3aed",
  children: [
    {
      id: "patho",
      label: "Pathogenesis",
      color: "#f38ba8",
      angle: -100,
      dist: 210,
      tooltip: "Complex interplay of genetic, environmental & immune factors leading to autoimmunity",
      children: [
        { id: "p1", label: "Type I IFN\nSignature", tooltip: "Plasmacytoid DCs produce excess IFN-α; striking interferon gene signature in blood cells" },
        { id: "p2", label: "TLR Activation\n(TLR7/TLR9)", tooltip: "Self-DNA/RNA activates TLR9/TLR7 on autoreactive B cells; requires defective nuclear clearance" },
        { id: "p3", label: "NETs & LDGs", tooltip: "Low-Density Granulocytes form NETs → release modified self-antigens → amplify type I IFN & vasculopathy" },
        { id: "p4", label: "Genetic Factors", tooltip: "HLA-DR2/DR3 (OR 2-5), C1q/C2/C4 deficiency, FcγRIIB polymorphism, PTPN22, TREX1" },
        { id: "p5", label: "UV Light\nTrigger", tooltip: "UV causes apoptosis of skin cells → nuclear antigen release → immune complex formation" },
        { id: "p6", label: "Immune Complex\nDeposition", tooltip: "Anti-nuclear antibodies form complexes that deposit in vessel walls, glomeruli → complement activation → tissue injury" },
      ]
    },
    {
      id: "clinical",
      label: "Clinical Features",
      color: "#fab387",
      angle: -30,
      dist: 220,
      tooltip: "Multisystem disease with remitting/relapsing course",
      children: [
        { id: "c1", label: "Mucocutaneous\n(80%)", tooltip: "Malar (butterfly) rash, discoid rash, photosensitivity, oral ulcers, alopecia, bullous lupus" },
        { id: "c2", label: "Musculoskeletal", tooltip: "Non-erosive symmetric arthritis/arthralgia; Jaccoud arthropathy; myositis" },
        { id: "c3", label: "Renal\n(Lupus Nephritis)", tooltip: "Class I-VI (ISN/RPS); Class IV diffuse GN most severe; red cell casts, proteinuria; major cause of morbidity" },
        { id: "c4", label: "Neuropsychiatric", tooltip: "Seizures, psychosis, cognitive dysfunction, stroke, transverse myelitis; MRI: white matter lesions, infarcts" },
        { id: "c5", label: "Cardiopulmonary", tooltip: "Pleuritis, pericarditis, Libman-Sacks endocarditis, accelerated atherosclerosis, pulmonary HTN" },
        { id: "c6", label: "Hematologic", tooltip: "AIHA (Coombs+), thrombocytopenia, leukopenia/lymphopenia, antiphospholipid syndrome (~21%)" },
        { id: "c7", label: "Constitutional", tooltip: "Fever, fatigue, weight loss – common during flares" },
      ]
    },
    {
      id: "antibodies",
      label: "Autoantibodies",
      color: "#a6e3a1",
      angle: 40,
      dist: 210,
      tooltip: "Multiple autoantibodies present; correlate with disease activity & organ involvement",
      children: [
        { id: "ab1", label: "ANA (~99%)", tooltip: "Antinuclear antibody – sensitive but not specific; entry criterion for EULAR/ACR classification" },
        { id: "ab2", label: "Anti-dsDNA\n(~70%)", tooltip: "High specificity for SLE; titers correlate with disease activity & nephritis flares" },
        { id: "ab3", label: "Anti-Sm\n(~38%)", tooltip: "Anti-Smith antibody – highly specific for SLE (low sensitivity)" },
        { id: "ab4", label: "Anti-Ro/La\n(49%/35%)", tooltip: "Anti-Ro (SSA) – neonatal lupus, photosensitivity; Anti-La (SSB) – Sjögren overlap" },
        { id: "ab5", label: "Antiphospholipid\n(~21%)", tooltip: "aCL, anti-β2GPI, lupus anticoagulant → thrombosis, recurrent pregnancy loss (APS)" },
        { id: "ab6", label: "Anti-RNP\n(~33%)", tooltip: "High titers → MCTD overlap; Anti-ribosomal P (~10%) → neuropsychiatric lupus" },
      ]
    },
    {
      id: "diagnosis",
      label: "Diagnosis",
      color: "#89dceb",
      angle: 110,
      dist: 215,
      tooltip: "Clinical diagnosis supported by lab findings; EULAR/ACR 2019 criteria are gold standard",
      children: [
        { id: "d1", label: "EULAR/ACR 2019\nCriteria", tooltip: "ANA ≥1:80 entry criterion; score ≥10 = SLE; weighted domains (clinical + immunological)" },
        { id: "d2", label: "Key Lab Tests", tooltip: "ANA, anti-dsDNA, anti-Sm, complement C3/C4, CBC, urinalysis with microscopy, creatinine" },
        { id: "d3", label: "Renal Biopsy", tooltip: "Guides management; identifies lupus nephritis class (I-VI); shows immune complex deposits, GN pattern" },
        { id: "d4", label: "Disease\nMonitoring", tooltip: "SLEDAI score, anti-dsDNA titers, complement levels (C3/C4 fall with active disease), urinalysis" },
        { id: "d5", label: "Imaging", tooltip: "MRI for NPSLE (white matter lesions, infarcts); echocardiography for cardiac involvement" },
      ]
    },
    {
      id: "treatment",
      label: "Treatment",
      color: "#cba6f7",
      angle: 170,
      dist: 220,
      tooltip: "Tailored to disease severity and organ involvement; aim for remission & damage prevention",
      children: [
        { id: "t1", label: "Hydroxychloroquine\n(Cornerstone)", tooltip: "200-400 mg/day (≤5 mg/kg); reduces flares, damage, mortality; safe in pregnancy; annual eye checks" },
        { id: "t2", label: "Corticosteroids", tooltip: "Prednisone 5-30 mg/day for moderate disease; IV methylprednisolone pulses for severe flares; limit long-term use" },
        { id: "t3", label: "Immunosuppressives", tooltip: "MMF (nephritis); Cyclophosphamide (severe nephritis/NPSLE); Azathioprine (maintenance/pregnancy); Methotrexate (skin/joints)" },
        { id: "t4", label: "Biologics", tooltip: "Belimumab (anti-BAFF); Anifrolumab (anti-IFN-R, approved 2021); Rituximab (refractory, off-label); Obinutuzumab (nephritis, NEJM 2025)" },
        { id: "t5", label: "Calcineurin\nInhibitors", tooltip: "Tacrolimus, cyclosporine, voclosporin (23.7 mg BID) – particularly for membranous lupus nephritis" },
        { id: "t6", label: "Adjuncts", tooltip: "ACE inhibitor/ARB for HTN + proteinuria; warfarin for APS thrombosis; IVIG for refractory/TTP; sunscreen" },
      ]
    },
    {
      id: "prognosis",
      label: "Prognosis",
      color: "#f9e2af",
      angle: -160,
      dist: 200,
      tooltip: "10-year survival >90% with modern therapy (was ~50% in 1950s)",
      children: [
        { id: "pr1", label: "Survival", tooltip: "10-year survival >90% with modern management; much improved vs historical outcomes" },
        { id: "pr2", label: "Causes of Death", tooltip: "Infection (immunosuppression), renal failure, cardiovascular disease (accelerated atherosclerosis), disease flares" },
        { id: "pr3", label: "Damage Accrual", tooltip: "Measured by SLICC Damage Index; irreversible organ damage accumulates over time" },
        { id: "pr4", label: "Pregnancy", tooltip: "Plan during remission; risk of pre-eclampsia, fetal loss; neonatal lupus if anti-Ro+; hydroxychloroquine continued" },
        { id: "pr5", label: "Epidemiology", tooltip: "F:M = 10:1; predominant in ages 20-60; higher incidence/severity in Black women (~1 in 250 vs 1 in 700 overall)" },
      ]
    }
  ]
};

// ── Layout ────────────────────────────────────────────────────────────────────
const svg = document.getElementById('mindmap');
const ns = 'http://www.w3.org/2000/svg';
let viewX = 0, viewY = 0, scale = 1;
let isDragging = false, dragStart = { x: 0, y: 0 }, viewStart = { x: 0, y: 0 };

function toRad(deg) { return deg * Math.PI / 180; }

function computePositions() {
  const nodes = [];
  const edges = [];
  const root = { id: 'root', x: cx, y: cy, label: mindmapData.sublabel, color: mindmapData.color, glow: mindmapData.glow, r: 54, isRoot: true, tooltip: 'Chronic multisystem autoimmune disease; classic immune complex disease; F:M = 10:1' };
  nodes.push(root);

  mindmapData.children.forEach((branch) => {
    const bAngle = toRad(branch.angle);
    const bx = cx + branch.dist * Math.cos(bAngle);
    const by = cy + branch.dist * Math.sin(bAngle);
    const bNode = { id: branch.id, x: bx, y: by, label: branch.label, color: branch.color, r: 38, isBranch: true, tooltip: branch.tooltip };
    nodes.push(bNode);
    edges.push({ from: root, to: bNode, color: branch.color, thick: true });

    const nKids = branch.children.length;
    branch.children.forEach((child, i) => {
      const spread = 70;
      const childAngle = bAngle + toRad(-spread/2 + (spread/(nKids-1||1))*i);
      const childDist = 150;
      const childX = bx + childDist * Math.cos(childAngle);
      const childY = by + childDist * Math.sin(childAngle);
      const cNode = { id: child.id, x: childX, y: childY, label: child.label, color: branch.color, r: 26, isLeaf: true, tooltip: child.tooltip };
      nodes.push(cNode);
      edges.push({ from: bNode, to: cNode, color: branch.color, thick: false });
    });
  });

  return { nodes, edges };
}

function getTransform() {
  return `translate(${viewX}, ${viewY}) scale(${scale})`;
}

function renderMindmap() {
  svg.innerHTML = '';

  // Defs
  const defs = document.createElementNS(ns, 'defs');

  // Radial gradient for root
  const rg = document.createElementNS(ns, 'radialGradient');
  rg.setAttribute('id', 'rootGrad');
  rg.innerHTML = `<stop offset="0%" stop-color="#9b59b6"/><stop offset="100%" stop-color="#6c3483"/>`;
  defs.appendChild(rg);

  // Glow filters
  ['f38ba8','fab387','a6e3a1','89dceb','cba6f7','f9e2af'].forEach((c, i) => {
    const f = document.createElementNS(ns, 'filter');
    f.setAttribute('id', `glow${i}`);
    f.setAttribute('x', '-50%'); f.setAttribute('y', '-50%');
    f.setAttribute('width', '200%'); f.setAttribute('height', '200%');
    f.innerHTML = `<feGaussianBlur stdDeviation="6" result="blur"/><feMerge><feMergeNode in="blur"/><feMergeNode in="SourceGraphic"/></feMerge>`;
    defs.appendChild(f);
  });

  // Root glow
  const rf = document.createElementNS(ns, 'filter');
  rf.setAttribute('id', 'rootGlow');
  rf.setAttribute('x', '-60%'); rf.setAttribute('y', '-60%');
  rf.setAttribute('width', '220%'); rf.setAttribute('height', '220%');
  rf.innerHTML = `<feGaussianBlur stdDeviation="12" result="blur"/><feMerge><feMergeNode in="blur"/><feMergeNode in="SourceGraphic"/></feMerge>`;
  defs.appendChild(rf);

  svg.appendChild(defs);

  const g = document.createElementNS(ns, 'g');
  g.setAttribute('id', 'main-group');
  g.setAttribute('transform', getTransform());
  svg.appendChild(g);

  const { nodes, edges } = computePositions();

  // Draw edges first
  edges.forEach(e => {
    const path = document.createElementNS(ns, 'path');
    const dx = e.to.x - e.from.x;
    const dy = e.to.y - e.from.y;
    const mx = e.from.x + dx * 0.5;
    const my = e.from.y + dy * 0.5;
    const d = `M ${e.from.x} ${e.from.y} Q ${mx} ${e.from.y} ${e.to.x} ${e.to.y}`;
    path.setAttribute('d', d);
    path.setAttribute('stroke', e.color);
    path.setAttribute('stroke-width', e.thick ? 3 : 1.8);
    path.setAttribute('fill', 'none');
    path.setAttribute('opacity', e.thick ? '0.7' : '0.5');
    path.setAttribute('stroke-linecap', 'round');
    g.appendChild(path);
  });

  // Draw nodes
  const colorGlowMap = {'#f38ba8':0,'#fab387':1,'#a6e3a1':2,'#89dceb':3,'#cba6f7':4,'#f9e2af':5};

  nodes.forEach(node => {
    const grp = document.createElementNS(ns, 'g');
    grp.setAttribute('cursor', 'pointer');
    grp.setAttribute('data-tooltip', node.tooltip || '');
    grp.setAttribute('data-label', node.label.replace(/\n/g, ' '));

    if (node.isRoot) {
      // Outer glow ring
      const glow = document.createElementNS(ns, 'circle');
      glow.setAttribute('cx', node.x); glow.setAttribute('cy', node.y);
      glow.setAttribute('r', node.r + 14);
      glow.setAttribute('fill', 'none');
      glow.setAttribute('stroke', '#a855f7');
      glow.setAttribute('stroke-width', '2');
      glow.setAttribute('opacity', '0.4');
      glow.setAttribute('filter', 'url(#rootGlow)');
      g.appendChild(glow);

      const circ = document.createElementNS(ns, 'circle');
      circ.setAttribute('cx', node.x); circ.setAttribute('cy', node.y);
      circ.setAttribute('r', node.r);
      circ.setAttribute('fill', 'url(#rootGrad)');
      circ.setAttribute('stroke', '#e0a3ff');
      circ.setAttribute('stroke-width', '2.5');
      circ.setAttribute('filter', 'url(#rootGlow)');
      grp.appendChild(circ);

      // Text lines
      const lines = node.label.split('\n');
      lines.forEach((line, i) => {
        const t = document.createElementNS(ns, 'text');
        t.setAttribute('x', node.x);
        t.setAttribute('y', node.y + (i - (lines.length-1)/2) * 16 + 1);
        t.setAttribute('text-anchor', 'middle');
        t.setAttribute('dominant-baseline', 'middle');
        t.setAttribute('fill', 'white');
        t.setAttribute('font-size', i === 0 ? '14' : '11');
        t.setAttribute('font-weight', i === 0 ? '800' : '500');
        t.setAttribute('pointer-events', 'none');
        t.textContent = line;
        grp.appendChild(t);
      });
    } else if (node.isBranch) {
      const glowIdx = colorGlowMap[node.color] || 0;
      const circ = document.createElementNS(ns, 'circle');
      circ.setAttribute('cx', node.x); circ.setAttribute('cy', node.y);
      circ.setAttribute('r', node.r);
      circ.setAttribute('fill', node.color + '33');
      circ.setAttribute('stroke', node.color);
      circ.setAttribute('stroke-width', '2.5');
      circ.setAttribute('filter', `url(#glow${glowIdx})`);
      grp.appendChild(circ);

      const lines = node.label.split('\n');
      lines.forEach((line, i) => {
        const t = document.createElementNS(ns, 'text');
        t.setAttribute('x', node.x);
        t.setAttribute('y', node.y + (i - (lines.length-1)/2) * 13 + 1);
        t.setAttribute('text-anchor', 'middle');
        t.setAttribute('dominant-baseline', 'middle');
        t.setAttribute('fill', node.color);
        t.setAttribute('font-size', '11.5');
        t.setAttribute('font-weight', '700');
        t.setAttribute('pointer-events', 'none');
        t.textContent = line;
        grp.appendChild(t);
      });
    } else {
      // Leaf - rounded rect
      const lines = node.label.split('\n');
      const rw = Math.max(...lines.map(l => l.length)) * 5.5 + 18;
      const rh = lines.length * 16 + 14;

      const rect = document.createElementNS(ns, 'rect');
      rect.setAttribute('x', node.x - rw/2);
      rect.setAttribute('y', node.y - rh/2);
      rect.setAttribute('width', rw);
      rect.setAttribute('height', rh);
      rect.setAttribute('rx', '10');
      rect.setAttribute('fill', node.color + '22');
      rect.setAttribute('stroke', node.color);
      rect.setAttribute('stroke-width', '1.5');
      grp.appendChild(rect);

      lines.forEach((line, i) => {
        const t = document.createElementNS(ns, 'text');
        t.setAttribute('x', node.x);
        t.setAttribute('y', node.y + (i - (lines.length-1)/2) * 14 + 1);
        t.setAttribute('text-anchor', 'middle');
        t.setAttribute('dominant-baseline', 'middle');
        t.setAttribute('fill', node.color);
        t.setAttribute('font-size', '10');
        t.setAttribute('font-weight', '600');
        t.setAttribute('pointer-events', 'none');
        t.textContent = line;
        grp.appendChild(t);
      });
    }

    // Hover tooltip
    grp.addEventListener('mouseenter', (e) => {
      const tt = document.getElementById('tooltip');
      const tip = grp.getAttribute('data-tooltip');
      const lbl = grp.getAttribute('data-label');
      if (!tip) return;
      tt.innerHTML = `<b>${lbl}</b>${tip}`;
      tt.style.display = 'block';
    });
    grp.addEventListener('mousemove', (e) => {
      const tt = document.getElementById('tooltip');
      tt.style.left = (e.clientX + 14) + 'px';
      tt.style.top = (e.clientY - 10) + 'px';
    });
    grp.addEventListener('mouseleave', () => {
      document.getElementById('tooltip').style.display = 'none';
    });

    g.appendChild(grp);
  });
}

// ── Pan & Zoom ────────────────────────────────────────────────────────────────
function applyTransform() {
  const g = document.getElementById('main-group');
  if (g) g.setAttribute('transform', getTransform());
}

function zoomIn() { scale = Math.min(scale * 1.25, 4); applyTransform(); }
function zoomOut() { scale = Math.max(scale * 0.8, 0.3); applyTransform(); }
function resetView() { viewX = 0; viewY = 0; scale = 1; applyTransform(); }

const wrapper = document.getElementById('canvas-wrapper');

wrapper.addEventListener('mousedown', e => {
  isDragging = true;
  dragStart = { x: e.clientX, y: e.clientY };
  viewStart = { x: viewX, y: viewY };
});
window.addEventListener('mousemove', e => {
  if (!isDragging) return;
  viewX = viewStart.x + (e.clientX - dragStart.x);
  viewY = viewStart.y + (e.clientY - dragStart.y);
  applyTransform();
});
window.addEventListener('mouseup', () => isDragging = false);

wrapper.addEventListener('wheel', e => {
  e.preventDefault();
  const delta = e.deltaY > 0 ? 0.9 : 1.1;
  const rect = svg.getBoundingClientRect();
  const mx = e.clientX - rect.left;
  const my = e.clientY - rect.top;
  viewX = mx - (mx - viewX) * delta;
  viewY = my - (my - viewY) * delta;
  scale = Math.max(0.3, Math.min(4, scale * delta));
  applyTransform();
}, { passive: false });

// Touch support
let lastTouchDist = null;
wrapper.addEventListener('touchstart', e => {
  if (e.touches.length === 1) {
    isDragging = true;
    dragStart = { x: e.touches[0].clientX, y: e.touches[0].clientY };
    viewStart = { x: viewX, y: viewY };
  }
});
wrapper.addEventListener('touchmove', e => {
  e.preventDefault();
  if (e.touches.length === 1 && isDragging) {
    viewX = viewStart.x + (e.touches[0].clientX - dragStart.x);
    viewY = viewStart.y + (e.touches[0].clientY - dragStart.y);
    applyTransform();
  } else if (e.touches.length === 2) {
    const dx = e.touches[0].clientX - e.touches[1].clientX;
    const dy = e.touches[0].clientY - e.touches[1].clientY;
    const dist = Math.sqrt(dx*dx + dy*dy);
    if (lastTouchDist) {
      scale = Math.max(0.3, Math.min(4, scale * (dist / lastTouchDist)));
      applyTransform();
    }
    lastTouchDist = dist;
  }
}, { passive: false });
wrapper.addEventListener('touchend', () => { isDragging = false; lastTouchDist = null; });

renderMindmap();
</script>
</body>
</html>

Running Command

ls -lh /home/daytona/workspace/sle-mindmap/

Your SLE mind map is ready! Download it here:

index

HTML File · HTML

What's included in the mind map:

The map has 6 color-coded branches radiating from the central SLE node:

Color	Branch	Key leaf nodes
🔴 Red	Pathogenesis	Type I IFN, TLR activation, NETs/LDGs, Genetic factors, UV trigger, Immune complexes
🟠 Orange	Clinical Features	Mucocutaneous, Musculoskeletal, Renal, Neuropsychiatric, Cardiopulmonary, Hematologic, Constitutional
🟢 Green	Autoantibodies	ANA, Anti-dsDNA, Anti-Sm, Anti-Ro/La, Antiphospholipid, Anti-RNP
🔵 Cyan	Diagnosis	EULAR/ACR 2019, Key labs, Renal biopsy, Monitoring, Imaging
🟣 Purple	Treatment	Hydroxychloroquine, Corticosteroids, Immunosuppressives, Biologics, Calcineurin inhibitors, Adjuncts
🟡 Yellow	Prognosis	Survival, Causes of death, Damage accrual, Pregnancy, Epidemiology

Interactive features:

Hover over any node to see a detailed tooltip with clinical facts
Drag to pan around the map
Scroll wheel / pinch to zoom in/out
Zoom In / Reset / Zoom Out buttons at the bottom

This is a shared conversation. Sign in to Orris to start your own chat.